Gene therapy for ALS symptoms
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests an experimental gene therapy called XT-150, which is given as an injection into the fluid around the spinal cord. The goal is to see if it is safe and to gather information that could help treat ALS muscle weakness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a formal ALS diagnosis (probable or definite).
- Your first ALS symptoms must have started within the last 3 years.
- Your breathing strength must be at least 60% of what is expected for your age, sex, and height.
- You can be on a stable dose of an approved ALS treatment or on no treatment, but you cannot have had Tofersen.
- You must not have certain implants (like a shunt, a diaphragm pacing system, or a tracheostomy) or major heart, lung, or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called SNUG01 for people with ALS (a disease that weakens muscles). The goal is to see if it's safe and might slow down the disease, especially for those diagnosed within the last 2 years.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This trial tests a personalized medicine approach for people with ALS caused by changes in the TARDBP gene. The treatment uses a custom-made molecule to target the genetic cause and may help slow the disease.
This study tests a single injection given into the spinal fluid (intrathecal) to see if it is safe and might slow down ALS. It uses a specially engineered virus (AAV9) to deliver a treatment directly to the nervous system.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.